Medical decision analysis of endoscopic surveillance of Barrett's oesophagus to prevent oesophageal adenocarcinoma

Aliment Pharmacol Ther. 2002 Jan;16(1):41-50. doi: 10.1046/j.1365-2036.2002.01146.x.

Abstract

Background: Barrett's oesophagus is associated with an increased risk of the development of oesophageal adenocarcinoma. Endoscopic surveillance every 2-5 years has been recommended to prevent death from adenocarcinoma.

Aim: To assess the cost-effectiveness of this strategy.

Methods: The incremental cost-effectiveness of surveillance (as compared to no surveillance) was analysed with a computer model of a Markov process.

Results: Compared to no surveillance, the incremental cost-effectiveness of bi-annual endoscopy is 16,695 dollars per life-year saved. Surveillance is less cost-effective if the incidence rate of oesophageal adenocarcinoma is low and the 5-year survival rate is high. For surveillance to be cost-effective, there should be little reduction in health-related quality of life following surgical oesophagectomy to prevent death. Moreover, endoscopic surveillance and oesophagectomy need to be efficacious in reliably diagnosing high-grade dysplasia and preventing deaths from cancer. If such ideal conditions of surveillance are not met, the cost per life-year saved could rise five-fold.

Conclusions: Endoscopic surveillance of patients with Barrett's oesophagus may be a cost-effective means to prevent death from oesophageal adenocarcinoma.

Publication types

  • Evaluation Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adenocarcinoma / economics*
  • Adenocarcinoma / etiology
  • Adenocarcinoma / prevention & control*
  • Barrett Esophagus / complications*
  • Barrett Esophagus / economics
  • Barrett Esophagus / pathology
  • Cost-Benefit Analysis
  • Decision Support Systems, Clinical*
  • Diagnosis, Differential
  • Endoscopy / economics*
  • Esophageal Neoplasms / economics*
  • Esophageal Neoplasms / etiology
  • Esophageal Neoplasms / prevention & control*
  • Esophagectomy
  • Female
  • Humans
  • Male
  • Markov Chains
  • Middle Aged
  • Quality of Life*
  • Survival Analysis